ABCELLERA BIOLOGICS INC (ABCL)

CA00288U1066 - Common Stock

3.31  +0.18 (+5.75%)

After market: 3.3686 +0.06 (+1.77%)

Fundamental Rating

3

Overall ABCL gets a fundamental rating of 3 out of 10. We evaluated ABCL against 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for ABCL as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, ABCL is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABCL had negative earnings in the past year.
ABCL had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ABCL reported negative net income in multiple years.
ABCL had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

ABCL has a Return On Assets (-12.62%) which is in line with its industry peers.
ABCL has a Return On Equity (-16.31%) which is in line with its industry peers.
Industry RankSector Rank
ROA -12.62%
ROE -16.31%
ROIC N/A
ROA(3y)4.03%
ROA(5y)2.91%
ROE(3y)5.04%
ROE(5y)1.61%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ABCL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABCL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABCL has been increased compared to 5 years ago.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ABCL has an Altman-Z score of 1.78. This is a bad value and indicates that ABCL is not financially healthy and even has some risk of bankruptcy.
ABCL has a Altman-Z score (1.78) which is comparable to the rest of the industry.
ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.78
ROIC/WACCN/A
WACC9.56%

2.3 Liquidity

ABCL has a Current Ratio of 9.34. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
ABCL has a better Current ratio (9.34) than 85.96% of its industry peers.
ABCL has a Quick Ratio of 9.34. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
ABCL's Quick ratio of 9.34 is amongst the best of the industry. ABCL outperforms 92.98% of its industry peers.
Industry RankSector Rank
Current Ratio 9.34
Quick Ratio 9.34

More info and screens

5

3. Growth

3.1 Past

ABCL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.56%.
The Revenue for ABCL has decreased by -34.60% in the past year. This is quite bad
Measured over the past years, ABCL shows a very strong growth in Revenue. The Revenue has been growing by 34.00% on average per year.
EPS 1Y (TTM)-35.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70%
Revenue 1Y (TTM)-34.6%
Revenue growth 3Y-45.37%
Revenue growth 5Y34%
Sales Q2Q%-1.39%

3.2 Future

The Earnings Per Share is expected to grow by 14.64% on average over the next years. This is quite good.
ABCL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.50% yearly.
EPS Next Y-16.71%
EPS Next 2Y-15.37%
EPS Next 3Y-5.81%
EPS Next 5Y14.64%
Revenue Next Year-17.17%
Revenue Next 2Y6.35%
Revenue Next 3Y21.24%
Revenue Next 5Y11.5%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABCL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ABCL's earnings are expected to decrease with -5.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.37%
EPS Next 3Y-5.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABCL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (1/6/2025, 7:13:58 PM)

After market: 3.3686 +0.06 (+1.77%)

3.31

+0.18 (+5.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-18 2025-02-18/amc
Inst Owners37.11%
Inst Owner Change0%
Ins Owners9.04%
Ins Owner Change0.18%
Market Cap977.67M
Analysts82.67
Price Target12.53 (278.55%)
Short Float %7.61%
Short Ratio6.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.6%
Min EPS beat(2)-9.89%
Max EPS beat(2)11.08%
EPS beat(4)2
Avg EPS beat(4)-1.86%
Min EPS beat(4)-26.05%
Max EPS beat(4)17.44%
EPS beat(8)4
Avg EPS beat(8)-216.48%
EPS beat(12)6
Avg EPS beat(12)-137.39%
EPS beat(16)6
Avg EPS beat(16)-115.25%
Revenue beat(2)0
Avg Revenue beat(2)-24.52%
Min Revenue beat(2)-29.29%
Max Revenue beat(2)-19.76%
Revenue beat(4)1
Avg Revenue beat(4)-14.42%
Min Revenue beat(4)-29.29%
Max Revenue beat(4)1.29%
Revenue beat(8)1
Avg Revenue beat(8)-22.89%
Revenue beat(12)4
Avg Revenue beat(12)-9.45%
Revenue beat(16)6
Avg Revenue beat(16)-14.26%
PT rev (1m)0%
PT rev (3m)-20.37%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.83%
EPS NY rev (1m)0%
EPS NY rev (3m)1.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-34.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.66
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 1
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.11
BVpS3.65
TBVpS3.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.62%
ROE -16.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)4.03%
ROA(5y)2.91%
ROE(3y)5.04%
ROE(5y)1.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.97%
Cap/Sales 234.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.34
Quick Ratio 9.34
Altman-Z 1.78
F-Score3
WACC9.56%
ROIC/WACCN/A
Cap/Depr(3y)327.25%
Cap/Depr(5y)307.6%
Cap/Sales(3y)78.13%
Cap/Sales(5y)55.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70%
EPS Next Y-16.71%
EPS Next 2Y-15.37%
EPS Next 3Y-5.81%
EPS Next 5Y14.64%
Revenue 1Y (TTM)-34.6%
Revenue growth 3Y-45.37%
Revenue growth 5Y34%
Sales Q2Q%-1.39%
Revenue Next Year-17.17%
Revenue Next 2Y6.35%
Revenue Next 3Y21.24%
Revenue Next 5Y11.5%
EBIT growth 1Y-47.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.03%
EBIT Next 3Y-3.68%
EBIT Next 5YN/A
FCF growth 1Y-223.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-152.3%
OCF growth 3YN/A
OCF growth 5YN/A